Trial Condition(s):
Multiple Dose escalation Phase I study of BAY1021189
15357
Not Available
Not Available
The primary objective of this study was to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of once daily 1.25, 5.0 and 10 mg and twice daily 5 mg of vericiguat administered orally as one or multiples of 1.25 mg IR-tablets over 7 days in 12 healthy male subjects (9 on active drug and 3 on placebo) per dose step.
- Healthy male subject - Age: 18 to 45 years (inclusive) at the first screening visit - Ethnicity: white - Body mass index (BMI): above/equal 18 and below/equal 29.9 kg/m²
- Incompletely cured pre-existing diseases for which it can be assumed that the absorption, distribution, metabolism, elimination and effects of the study drugs will not be normal - Known hypersensitivity to the study drug (active substances or excipients of the preparations) - Known severe allergies, non-allergic drug reactions, or multiple drug allergies - Relevant diseases within the last 4 weeks prior to study drug administration - Febrile illness within 1 week before study drug administration - History of postural syncopes - Regular use of medicines - Regular use of therapeutic or recreational drugs - Use of medication within 2 weeks before study drug administration which could oppose the study objectives or which might influence them
Locations | Status | |
---|---|---|
Locations Investigative Site Wuppertal, Germany, 42113 | Status Completed | Contact Us: E-mail: [email protected] Phone: Not Available |
Multiple dose escalation study to investigate safety, tolerability, pharmacokinetics and pharmacodynamics of BAY 1021189 after oral dosing of 1.25, 5, 10 mg OD and 5 mg BID over 7 days given as 1.25 mg or multiples of 1.25 mg IR-tablet in 12 healthy male subjects per dose step in a randomized, single-blind, placebo-controlled, group-comparison design
Trial Type:
Interventional
Intervention Type:
Drug
Trial Purpose:
Basic Science
Allocation:
Randomized
Blinding:
N/A
Assignment:
N/A
Trial Arms:
5
Not Available